Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Wolz OO, Vahrenhorst D, Quintini G, Lemberg C, Koch SD, Kays SK, Walz L, Kulkarni N, Fehlings M, Wengenmayer P, Heß J, Oostvogels L, Lazzaro S, von Eisenhart-Rothe P, Mann P. Wolz OO, et al. Among authors: walz l. Vaccines (Basel). 2024 Apr 6;12(4):388. doi: 10.3390/vaccines12040388. Vaccines (Basel). 2024. PMID: 38675770 Free PMC article.
N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer's disease.
Jörg M, Plehn JE, Kristen M, Lander M, Walz L, Lietz C, Wijns J, Pichot F, Rojas-Charry L, Wirtz Martin KM, Ruffini N, Kreim N, Gerber S, Motorin Y, Endres K, Rossmanith W, Methner A, Helm M, Friedland K. Jörg M, et al. Among authors: walz l. Mol Psychiatry. 2024 Jan 29. doi: 10.1038/s41380-024-02421-y. Online ahead of print. Mol Psychiatry. 2024. PMID: 38287100
Life expectancy in multiple sclerosis by EDSS score.
Walz L, Brooks JC, Shavelle RM, Robertson N, Harding KE. Walz L, et al. Mult Scler Relat Disord. 2022 Dec;68:104219. doi: 10.1016/j.msard.2022.104219. Epub 2022 Oct 5. Mult Scler Relat Disord. 2022. PMID: 36244189
Influenza A virus infection instructs hematopoiesis to megakaryocyte-lineage output.
Rommel MGE, Walz L, Fotopoulou F, Kohlscheen S, Schenk F, Miskey C, Botezatu L, Krebs Y, Voelker IM, Wittwer K, Holland-Letz T, Ivics Z, von Messling V, Essers MAG, Milsom MD, Pfaller CK, Modlich U. Rommel MGE, et al. Among authors: walz l. Cell Rep. 2022 Oct 4;41(1):111447. doi: 10.1016/j.celrep.2022.111447. Cell Rep. 2022. PMID: 36198277 Free article.
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L; HERALD Study Group. Kremsner PG, et al. Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23. Lancet Infect Dis. 2022. PMID: 34826381 Free PMC article. Clinical Trial.
73 results